| 2023-11-28 | +0.27 % |
|
| 2023-11-27 | -1.12 % |
|
| 2023-11-16 | +1.06 % |
|
| 2023-11-10 | +1.49 % |
|
| 2023-11-09 | -3.69 % |
|
| 2023-11-08 | -3.74 % |
|
| 2023-11-03 | +4.12 % |
|
| 2023-10-31 | +2.33 % |
|
| 2023-10-24 | +1.32 % |
|
| 2023-10-19 | +1.21 % |
|
| 2023-10-16 | +0.9 % |
|
| 2023-10-11 | +0.74 % |
|
| 2023-10-09 | -0.2 % |
|
| 2023-09-27 | +0.26 % |
|
| 2023-09-26 | -1.58 % |
|
| 2023-09-25 | -1.03 % |
|
| 2023-09-21 | -5.02 % |
|
| 2023-09-20 | +0.05 % |
|
| 2023-09-18 | +1.29 % |
|
| 2023-09-15 | +0.06 % |
|
| 2023-09-14 | +2.04 % |
|
| 2023-09-13 | +3.3 % |
|
| 2023-09-11 | -0.04 % |
|
| 2023-09-06 | +0.07 % |
|
| 2023-08-30 | +2.84 % |
|
| 2023-08-28 | -0.81 % |
|
| 2023-08-24 | -1.67 % |
|
| 2023-08-23 | +0.89 % |
|
| 2023-08-09 | +4.64 % |
- The article discusses the financial performance of Charles River Laboratories (CRL) in the second quarter of 2023, reporting an 8.9% increase in revenue compared to the same period in the previous year, with an organic growth rate of 11.2%. The stock price of CRL also went up by 4.64% the previous night. The article does not provide specific reasons for the stock increase.
- The stock of Charles River Laboratories International Inc (CRL) went up by 4.64% last night, and the article suggests that the stock may be significantly undervalued based on a detailed valuation analysis. The company is a leading provider of drug discovery and development services, and its stock price currently stands at $214.47 with a market cap of $11 billion. The article highlights the company's financial strength, profitability, and growth as factors that contribute to its undervaluation.
- The article states that Charles River Laboratories International Inc (CRL) stock went up by 4.52% yesterday and attributes this increase to the company's impressive performance in the Medical Diagnostics & Research industry, including its high Financial Strength Rank, profitability, growth, valuation, and positive momentum.
|
| 2023-08-04 | +2.66 % |
|
| 2023-08-03 | -2.17 % |
|
| 2023-08-01 | -0.11 % |
|
| 2023-07-31 | -0.45 % |
|
| 2023-07-20 | -0.01 % |
|
| 2023-07-19 | +1.33 % |
|
| 2023-07-18 | -3.82 % |
|
| 2023-07-17 | +0.86 % |
|
| 2023-07-14 | -0.76 % |
|
| 2023-07-13 | -0.87 % |
|
| 2023-07-12 | +1.29 % |
|
| 2023-07-10 | +0.92 % |
|
| 2023-07-07 | -0.23 % |
|
| 2023-07-06 | +0.21 % |
|
| 2023-07-05 | -0.84 % |
|
| 2023-07-03 | -0.75 % |
|
| 2023-06-30 | +0.51 % |
|
| 2023-06-29 | +1.67 % |
|
| 2023-06-28 | +0.69 % |
|
| 2023-06-27 | -0.95 % |
|
| 2023-06-26 | -0.73 % |
|
| 2023-06-23 | +1.78 % |
|
| 2023-06-22 | -1.04 % |
|
| 2023-06-21 | -1.54 % |
|
| 2023-06-20 | -0.22 % |
|
| 2023-06-16 | +0.49 % |
|
| 2023-06-15 | +0.75 % |
|
| 2023-06-14 | -0.28 % |
|
| 2023-06-13 | +1.23 % |
|
| 2023-06-12 | +3.95 % |
|
| 2023-06-09 | -2.7 % |
|
| 2023-06-08 | -0.14 % |
- A class action securities lawsuit has been filed against Charles River Laboratories due to alleged securities fraud between May 5, 2020, and February 21, 2023, which has caused its stock to go down by 0.14%.
- The Gross Law Firm is encouraging shareholders who purchased shares of Charles River Laboratories International, Inc. (CRL) between May 5, 2020, and February 21, 2023, to contact them regarding possible lead plaintiff appointment due to the complaint alleging that the company engaged in illegal importation of non-human primates for research, which puts the company at a heightened risk of criminal and regulatory investigation, leading to a suspension of shipments of primates from Cambodia, and that the company's positive statements about its business, operations, and prospects were materially misleading and/or lacked a reasonable basis. This news may have contributed to the -0.14% decrease in CRL stock.
- The law firm Pomerantz LLP is investigating claims of securities fraud or other unlawful business practices by Charles River Laboratories International, Inc., after the company received a subpoena from the US Department of Justice regarding its transport of primates for research purposes, causing the stock price to fall.
|
